<DOC>
	<DOCNO>NCT02988882</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety OTX-DP compare Placebo Drug Delivery Vehicle ( PV ) treatment sign symptom chronic allergic conjunctivitis .</brief_summary>
	<brief_title>Study Evaluating Efficacy Safety OTX-DP Treatment Chronic Allergic Conjunctivitis Using Modified Conjunctival Allergen Challenge Model ( CAC® )</brief_title>
	<detailed_description />
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis , Allergic</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>1. least 18 year age either sex race ; 2. provide write informed consent sign HIPAA form ; 3. willing able follow instruction attend study visit ; 4 . ( female capable become pregnant ) agree urine pregnancy test perform screening ( must negative ) exit visit ; must lactate ; must agree use medically acceptable form birth control throughout study duration least 14 day prior insertion investigational product ( Visit 3b ) one month investigational product removal . Women consider capable become pregnant include female experience menarche experience menopause ( define amenorrhea great 12 consecutive month ) undergo successful surgical sterilization ( hysterectomy , bilateral tubal ligation , bilateral oophorectomy ) ; 5. positive history ocular allergy positive skin test reaction perennial allergen ( cat dander , dog dander , dust mite , cockroach ) seasonal allergen ( tree , grass , and/or ragweed ) confirm allergic skin test give subject 's Screening visit ; 6. calculate visual acuity 0.7 logMAR good eye measure use ETDRS chart ; 7. positive bilateral CAC® reaction perennial allergen within 10 ( ±2 ) minute instillation last titration allergen Visit 1 ; 8. positive bilateral CAC® reaction3 least two three time point follow challenge Visit 2a 2b ; 9. average ≥ 3 itch ≥2.5 conjunctival redness eye postCAC® assessment Visit 3a ; 10. able willing avoid disallow medication appropriate washout period study ( see exclusion 6 ) ; 11. able willing discontinue wear contact lens least 72 hour prior study trial period . 1. known contraindication sensitivity use investigational product medication component ; 2. ocular condition , opinion investigator , could affect subject 's safety trial parameter ( include limit narrow angle glaucoma , clinically significant blepharitis , follicular conjunctivitis , iritis , pterygium diagnosis dry eye ) ; 3. history refractive surgery ( include LASIK procedure ) within past 2 year ; 4. know history retinal detachment , diabetic retinopathy , active retinal disease ; 5. presence active ocular infection ( bacterial , viral fungal ) , positive history ocular herpetic infection visit ; 6. use follow disallowed medications* period indicate prior Visit 1 study : 7 Days systemic ocular H1 antihistamine , H1 antihistamine/mastcell stabilizer drug combination , H1 antihistamine vasoconstrictor drug combination ; decongestant ; monoamine oxidase inhibitor ; topical ophthalmic preparation ( include artificial tear ) ; lid scrub ; prostaglandins prostaglandin derivative ; ocular , topical , systemic nonsteroidal antiinflammatory drug ( NSAIDs ) ; 14 Days inhale , ocular topical corticosteroid mast cell stabilizer ; 45 Days depotcorticosteroids ; *Note : Currently market overthecounter antiallergy eye drop ( ie antihistamine/ vasoconstrictor combination product Visine®A® ) may administer subject end subject 's last visit , evaluation complete ; 7. congenital ocular anomaly ( include punctal lid ectropion , entropion , trichiasis , supernumerary puncta ) anomalies punctum ( include lack good punctal apposition eye ) ; 8. current diagnosis history Herpes Simplex Keratitis ; 9. diagnosis significant illness [ eg , autoimmune disease , severe cardiovascular disease ( include arrhythmia ) , condition require immunosuppressive cancer chemotherapeutic agent ] . This include limited : alcohol drug abuse , hypertension , diabetes , rheumatoid arthritis , lupus , thyroid disease , Parkinson 's disease , hepatitis , scleroderma , vitamin deficiency , Sjögren 's syndrome , history status asthmaticus , know history persistent moderate severe asthma , know history moderate severe allergic asthmatic reaction study allergen ; 10. score &gt; 0 itch and/or &gt; 1 conjunctival redness prior challenge ( Visit 1 ) either eye ; 11. plan surgery ( ocular systemic ) trial period within 30 day ; 12. use investigational drug medical device within 30 day study concurrently enrol another investigational product trial ; 13. female currently pregnant , planning pregnancy , lactating , use medically acceptable form birth control throughout study duration least 14 day prior insertion investigational product one month investigational product removal , positive urine pregnancy test Visit 1 ; 14. intraocular pressure le 5 mmHg great 22 mmHg type glaucoma Visit 1 ; 15. history IOP increase result steroid treatment . 16 . Punctum size small 0.4 mm great equal 1.0 mm ; 17 . Punctum small allow transient dilation 0.7 mm prior insertion OTXDP PV .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>